Open AccessSelf‐Reported Cognitive Impairment After Breast Cancer Treatment in Young Women from the ELIPPSE40 Cohort: The Long‐Term Impact of Chemotherapy
Author(s) -
Rey Dominique,
Bouhnik AnneDéborah,
Mancini Julien,
Bendiane MarcKarim,
Séror Valérie,
Viens Patrice
Publication year - 2012
Publication title -
the breast journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.533
H-Index - 72
eISSN - 1524-4741
pISSN - 1075-122X
DOI - 10.1111/j.1524-4741.2012.01275.x
Subject(s) - medicine , breast cancer , cohort , telephone interview , medical prescription , cancer , cohort study , quality of life (healthcare) , psychiatry , family medicine , pediatrics , gerontology , gynecology , social science , nursing , sociology , pharmacology
Abstract: Cognitive impairment (CI) is common after cancer treatments, but little is known about the long‐term evolution of CI, especially in premenopausal women. Since September 2005, all consecutive women included in the French National Health Insurance Fund registry with a diagnosis of primary breast cancer, aged 18–40 years and living in South Eastern France, were asked to participate in a cohort study, including telephone interviews, medical data, and prescription refills of psychotropic drugs and adjuvant endocrine therapy. At each interview, CI is defined as self‐report of frequent memory loss and attention deficits. As of February 2010, 222 women with available medical data had taken part in the 10‐, 16‐, and 28‐month telephone interviews, with CI being reported by 37.4%, 36.5%, and 42.3% of participants, respectively. Tranquilizers’ dispensation was associated with CI self‐report at all three interviews; chemotherapy was reported only at the 28‐month interview. At 28 months, besides chemotherapy and tranquilizer’s dispensation, having a low educational level and not being a native French woman were also independently associated with CI. Reports of CI were common in young women and primarily related to psycho‐social vulnerabilities and cancer treatment. As they affect quality of life, long‐term CI complaints deserve greater consideration.